Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 20/20 | 0.65 |
| ▸ | PIK3CG | P48736 | 20/20 | 0.65 |
| ▸ | PIK3R2 | O00459 | 12/20 | 0.65 |
| ▸ | PIK3R1 | P27986 | 5/20 | 0.63 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.51 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15306774 | 0.91 | PIK3CD (0.78) | PIK3CDPIK3CGPIK3R2PIK3R1PIK3CA | |
| SCHEMBL16417398 | 0.91 | PIK3CD (0.67) | PIK3CDPIK3CGPIK3R2PIK3R1PIK3CA | |
| SCHEMBL16417394 | 0.89 | PIK3CD (0.64) | PIK3CDPIK3CGPIK3R2PIK3R1PIK3CA | |
| SCHEMBL16417342 | 0.87 | PIK3CD (0.66) | PIK3CDPIK3CGPIK3R2PIK3R1PIK3CA | |
| SCHEMBL16417366 | 0.86 | PIK3CD (0.68) | PIK3CDPIK3CGPIK3R2PIK3R1PIK3CA | |
| SCHEMBL16417304 | 0.86 | PIK3CD (0.59) | PIK3CDPIK3CGPIK3R2PIK3R1PIK3CA | |
| SCHEMBL17589970 | 0.86 | PIK3CD (0.63) | PIK3CDPIK3CGPIK3R2PIK3R1PIK3CA | |
| SCHEMBL16417369 | 0.86 | PIK3CD (0.61) | PIK3CDPIK3CGPIK3R2PIK3R1PIK3CA | |
| SCHEMBL16417368 | 0.85 | PIK3CD (0.60) | PIK3CDPIK3CGPIK3R2PIK3R1PIK3CA | |
| SCHEMBL16417382 | 0.85 | PIK3CD (0.60) | PIK3CDPIK3CGPIK3R2PIK3R1PIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8940742-B2 | Heterocyclic compounds and uses thereof | INFINITY PHARMACEUTICALS, INC. (US) | 2015-01-27 | — | — | US | disclosed |